EW vs. BSX, SYK, MDT, BDX, IDXX, RMD, DXCM, STE, PODD, and BAX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences vs.
Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
Boston Scientific presently has a consensus price target of $107.39, indicating a potential upside of 1.13%. Edwards Lifesciences has a consensus price target of $79.95, indicating a potential upside of 4.89%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Boston Scientific.
Edwards Lifesciences received 282 more outperform votes than Boston Scientific when rated by MarketBeat users. Likewise, 70.85% of users gave Edwards Lifesciences an outperform vote while only 69.87% of users gave Boston Scientific an outperform vote.
Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
In the previous week, Edwards Lifesciences had 30 more articles in the media than Boston Scientific. MarketBeat recorded 87 mentions for Edwards Lifesciences and 57 mentions for Boston Scientific. Boston Scientific's average media sentiment score of 0.92 beat Edwards Lifesciences' score of 0.69 indicating that Boston Scientific is being referred to more favorably in the media.
89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 0.5% of Boston Scientific shares are owned by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Edwards Lifesciences has a net margin of 70.82% compared to Boston Scientific's net margin of 11.07%. Edwards Lifesciences' return on equity of 20.76% beat Boston Scientific's return on equity.
Boston Scientific has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Summary
Edwards Lifesciences beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Edwards Lifesciences Competitors List
Related Companies and Tools
This page (NYSE:EW) was last updated on 2/17/2025 by MarketBeat.com Staff